Meeting
2013 ASCO Annual Meeting
Use of axitinib, a new-generation tyrosine kinase inhibitor, to decrease glioblastoma growth despite primary resistance to the VEGF-antibody bevacizumab.
Authors
Tobias Kratzsch
Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany
Tobias Kratzsch , Viktor Gruenwald , Peter Vajkoczy , Susanne Antje Kuhn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2077)
DOI
10.1200/jco.2013.31.15_suppl.2077
Abstract #
2077
Poster Bd #
6A
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).
First Author: Martin J. Van Den Bent
Poster
2014 ASCO Annual Meeting
Expression profile of angiogenic factors in paired initial and recurrent glioblastoma.
First Author: Emeline Tabouret
Poster
2013 Gastrointestinal Cancers Symposium
Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV + chemotherapy (CT): Biomarker findings from ML18147.
First Author: Stefan Kubicka
Poster
2023 ASCO Annual Meeting
A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non–small-cell lung cancer.
First Author: Melissa Lynne Johnson